English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT

Released

Journal Article

Genetic suppression of atrial fibrillation using a dominant-negative ether-a-go-go-related gene mutant

MPS-Authors
/persons/resource/persons93829

Koenen,  Michael
Department of Molecular Neurobiology, Max Planck Institute for Medical Research, Max Planck Society;

External Resource
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)
There are no public fulltexts stored in PuRe
Supplementary Material (public)
There is no public supplementary material available
Citation

Soucek, R., Thomas, D., Kelemen, K., Bikou, O., Seyler, C., Voss, F., et al. (2012). Genetic suppression of atrial fibrillation using a dominant-negative ether-a-go-go-related gene mutant. Heart Rhythm, 9(2), 265-272. doi:10.1016/j.hrthm.2011.09.008.


Cite as: https://hdl.handle.net/11858/00-001M-0000-0024-1F9A-D
Abstract
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. Gene therapy−dependent modulation of atrial electrophysiology may provide a more specific alternative to pharmacological and ablative treatment strategies. Objective We hypothesized that genetic inactivation of atrial repolarizing ether−a−go−go−related gene (ERG) K+ currents using a dominant−negative mutant would provide rhythm control in AF. Methods Ten domestic swine underwent pacemaker implantation and were subjected to atrial burst pacing to induce persistent AF. Animals were then randomized to receive either AdCERG−G627S to suppress ERG/IKr currents or green fluorescent protein (AdGFP) as control. Adenoviruses were applied using a novel hybrid technique employing atrial virus injection followed by epicardial electroporation to increase transgene expression. Results In pigs treated with AdCERG−G627S, the onset of persistent AF was prevented (n = 2) or significantly delayed compared to AdGFP controls (12 ± 2.1 vs. 6.2 ± 1.3 days; P < .001) during 14 day follow−up. Effective refractory periods were prolonged in the AdCERG−G627S group compared to AdGFP animals (221.5 ± 4.7 ms vs. 197.0 ± 4.7 ms; P < .006). Impairment of left ventricular ejection fraction (LVEF) during AF was prevented by AdCERG−G627S application (LVEFCERG−G627S = 62.1 ± 4.0% vs. LVEFGFP = 30.3 ± 9.1%; P < .001). Conclusion Inhibition of ERG function using atrial AdCERG−G627S gene transfer suppresses or delays the onset of persistent AF by prolongation of atrial refractoriness in a porcine model. Targeted gene therapy represents an alternative to pharmacological or ablative treatment of AF